CNQ · MDMA.CN
Pharmala Biotech Holdings Inc.
CA$0.16CA$0.00 (0.0%)
Pharmala Biotech Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.52% below the high.
Loading market information…
TSXV · MPH.V · CAD
Stock price, earnings
Quote as of Oct 29, 2026, 02:47 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
Medicure Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.11% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Medicure Inc.’s next earnings report is currently expected on Nov 19, 2026, with estimated earnings per share of -CA$0.04. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Medicure Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Medicure Inc. is a biopharmaceutical firm focused on developing, researching, and commercializing therapeutic solutions for cardiovascular conditions across Canada and the United States. Its product portfolio includes AGGRASTAT, an injectable glycoprotein GP IIb/IIIa receptor antagonist prescribed for acute coronary syndromes, such as unstable angina and non-Q-wave myocardial infarction. The company also provides ZYPITAMAG, a medication used to manage primary hyperlipidemia and mixed dyslipidemia. Additionally, Medicure offers the ReDS system, a non-invasive medical device designed to measure lung fluid levels, aiding in the management of congestive heart failure. Another key offering is Sodium Nitroprusside injection, utilized for rapidly lowering blood pressure during hypertensive crises in both adult and pediatric patients, inducing controlled hypotension for surgical bleeding reduction, and treating acute congestive heart failure. These products are made available through both retail pharmacy networks and online platforms. Established in 1997, Medicure Inc. is headquartered in Winnipeg, Canada.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:44 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2024 | Nov 25, 2024 | CA$0.07+263.0% vs estimate | CA$5.15M-20.45% vs estimate |
|---|
| Q2 2024 | Aug 14, 2024 | -CA$0.12-33.33% vs estimate | CA$5.17M+11.31% vs estimate |
|---|
| Q1 2024 | May 28, 2024 | CA$0.00+112.25% vs estimate | CA$5.69M+22.72% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$0.16CA$0.00 (0.0%)
Pharmala Biotech Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.52% below the high.
CA$0.79CA$0.00 (0.0%)
Crescita Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
CA$0.03CA$0.00 (0.0%)
Red Light Holland Corp.’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
CA$0.04-CA$0.02 (-27.27%)
Lobe Sciences Ltd.’s quoted price sits in the lower half of its reported 52-week range, 77.78% below the high.
CA$0.35CA$0.00 (0.0%)
Comprehensive Healthcare Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.92% below the high.
CA$0.12CA$0.00 (0.0%)
Marvel Biosciences Corp.’s quoted price sits in the lower half of its reported 52-week range, 52.0% below the high.
CA$0.02+CA$0.01 (+50.0%)
Blueberries Medical Corp.’s quoted price sits in the upper half of its reported 52-week range, 25.0% below the high.
CA$0.03CA$0.00 (0.0%)
Christina Lake Cannabis Corp.’s quoted price sits in the lower half of its reported 52-week range, 44.44% below the high.
